Lymphoma Treatment Market to Reach USD 15.01 Billion by 2030, Driven by Immunotherapy, CAR-T Therapies & Expanding Early Diagnosis

Mordor Intelligence has published a new report on lymphoma treatment market offering a comprehensive analysis of trends, growth drivers, and future projection

Introduction

The lymphoma treatment market size reached USD 10.02 billion in 2025 and is on track to achieve USD 15.01 billion by 2030, reflecting a steady 8.42% CAGR. The growth reflects increasing incidence rates of lymphoma worldwide, broader approvals of novel therapies, and expanding access to advanced treatment in emerging regions. Stakeholders in oncology care, pharmaceutical development, and global healthcare providers are closely monitoring this upward trajectory as the demand for effective lymphoma therapies rises.

This press release presents a detailed overview of the lymphoma treatment market, highlighting major trends, market segmentation, and key players shaping its future.

Report Overview:

https://www.mordorintelligence.com/industry-reports/lymphoma-treatment-market?utm_source=openpr

Key Trends

Rising Incidence and Increased Diagnosis

A major driver of growth in the lymphoma treatment market is the rising global incidence of lymphoma. As more cases of both non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are diagnosed aided by improved diagnostics and increased awareness demand for effective treatments is growing accordingly. Improved diagnostic capabilities, including better subtype identification, help ensure patients receive the most appropriate therapies earlier, thereby fueling demand for a broad spectrum of lymphoma treatments.

Shift Toward Immunotherapy and Advanced Cellular Treatments

The market is witnessing a strong shift away from traditional chemotherapy toward advanced biologics, immunotherapies, and cell-based therapies. Immunotherapy already commands a significant share of the market, with monoclonal antibodies and immune-modulating agents widely used in multiple lines of therapy.

Delivery Methods Evolving: From Intravenous to Convenient Subcutaneous and Oral Options

Traditionally, intravenous (IV) administration has dominated lymphoma treatments due to clinical protocols and the complexity of therapies. In 2024, IV delivery accounted for roughly 70% of the market share.

However, there is a clear trend toward more convenient delivery methods. Subcutaneous (SC) formulations are gaining traction, driven by patient preference for shorter clinic times and simpler dosing routines. SC delivery, expected to grow at double-digit CAGR, offers the possibility of outpatient or even home-based administration over time.

Geographic Expansion and Growing Treatment Access

While North America remains the largest regional market, accounting for over one-third of global revenue, emerging regions especially the Asia Pacific are expected to register the fastest growth over the forecast period.

Market Segmentation

The lymphoma treatment market can be broken down across multiple dimensions: disease type, therapy type, mode of administration, and end user. Below are the key segmentation patterns observed:

By Disease Type

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

By Type of Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

CAR-T Cell Therapy

Radiotherapy

Stem-Cell Transplantation

By Mode of Administration

Intravenous

Sub-cutaneous

Oral

By End User

Hospitals

Specialty Cancer Centres

Academic & Research Institutes

Home-care Settings

By Geography

North America

South Amerca

Middle east&Africa

Europe

Asia pacific

This segmentation highlights how the lymphoma treatment market is diversifying - not just in terms of therapy classes, but also in how and where treatments are delivered.

Key Players

The global lymphoma treatment market comprises multiple major pharmaceutical companies and biotech firms that develop, manufacture, and commercialize therapies across lymphoma subtypes and treatment modalities. These companies are instrumental in bringing immunotherapies, CAR-T therapies, targeted agents, and biologics to market.

Bristol-Myers Squibb Company

Merck & Co., Inc.

Novartis AG

Gilead Sciences

F. Hoffmann-La Roche Ltd

As treatment protocols evolve and newer agents gain approval, competition intensifies especially among companies developing next-generation immunotherapies and CAR-T constructs with improved safety, efficacy, and dosing convenience. The active pipeline and expanding global footprint of these players are key elements shaping future dynamics of the lymphoma treatment market.

Conclusion

The global lymphoma treatment market is on a clear upward path, with the projected value of USD 15.01 billion by 2030 signaling robust demand and growing adoption of advanced therapies. Shifts in treatment paradigms from chemotherapy toward immunotherapy, CAR-T cell therapy, and targeted agents combined with evolving delivery methods such as subcutaneous and oral formats, help broaden access and improve patient experience.

Increasing incidence of lymphoma, improved diagnostics, regulatory support for novel therapies, and expansion of healthcare infrastructure especially in emerging regions all contribute to the rising relevance of lymphoma treatments worldwide. Market segmentation across disease type, therapy modality, administration mode, and care setting underscores how diverse and dynamic the landscape has become.



For complete market analysis, please visit the Mordor Intelligence page:

https://www.mordorintelligence.com/industry-reports/lymphoma-treatment-market?utm_source=openpr

Industry related Reports:

Global Hodgkin Lymphoma Treatment Market: The Hodgkin lymphoma treatment market is segmented based on treatment type, including chemotherapy, radiotherapy, and other therapeutic approaches; stage of disease, covering early-stage (I-II), advanced-stage (III-IV), and additional classifications; patient age group, such as pediatric and adolescent, adult, and other age categories; and route of administration, including intravenous, oral, and other methods. The market is also analyzed across key geographies, namely North America, Europe, Asia-Pacific, and other regions. Market forecasts are presented in terms of value, measured in USD.

Get more Insights: https://www.mordorintelligence.com/industry-reports/hodgkins-lymphoma-treatment-market?utm_source=openpr

Lymphedema Treatment Market: The Lymphedema Treatment Market report presents a comprehensive analysis of the industry, with segmentation based on treatment type, including compression therapy, laser therapy, and other available options. It further classifies the market by type into secondary and primary lymphedema, as well as by affected area such as the lower extremity, upper extremity, and other regions. Additionally, the report examines end users, encompassing hospitals, specialty clinics, ambulatory surgical centers, and others, while providing a detailed geographical outlook across North America, Europe, Asia Pacific, and other regions. Market forecasts in the report are provided in terms of value (USD).

Get more Insights: https://www.mordorintelligence.com/industry-reports/lymphedema-treatment-market?utm_source=openpr

Non-Hodgkin Lymphoma Therapeutics Market: The Non-Hodgkin Lymphoma Therapeutics Market Report presents a detailed analysis of the industry, segmenting the market by therapy type including chemotherapy, radiation therapy, targeted therapy, immunotherapy, and other treatment options along with cell type, such as B-cell and T-cell lymphomas. The report further categorizes the market based on treatment line, covering first-line, second-line, and third-line and refractory therapies, and provides a comprehensive geographic analysis across North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Market forecasts are provided in terms of value (USD).

Get more Insights: https://www.mordorintelligence.com/industry-reports/non-hodgkins-lymphoma-therapeutics-market?utm_source=openpr



About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.